{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T19:18:36Z","timestamp":1794079116439,"version":"4.8.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute","award":["P30 CA023100"],"award-info":[{"award-number":["P30 CA023100"]}]},{"name":"National Cancer Institute","award":["P30 CA023100"],"award-info":[{"award-number":["P30 CA023100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs) can be isolated from the blood and other body fluids. This review will focus on current technologies and clinical applications for liquid biopsies. ctDNA\/cfDNA has been isolated and analyzed using many techniques, e.g., droplet digital polymerase chain reaction, beads, emulsion, amplification, and magnetics (BEAMing), tagged-amplicon deep sequencing (TAm-Seq), cancer personalized profiling by deep sequencing (CAPP-Seq), whole genome bisulfite sequencing (WGBS-Seq), whole exome sequencing (WES), and whole genome sequencing (WGS). CTCs have been isolated using biomarker-based cell capture, and positive or negative enrichment based on biophysical and other properties. ctDNA\/cfDNA and CTCs are being exploited in a variety of clinical applications: differentiating unique immune checkpoint blockade response patterns using serial samples; predicting immune checkpoint blockade response based on baseline liquid biopsy characteristics; predicting response and resistance to targeted therapy and chemotherapy as well as immunotherapy, including CAR-T cells, based on serial sampling; assessing shed DNA from multiple metastatic sites; assessing potentially actionable alterations; analyzing prognosis and tumor burden, including after surgery; interrogating difficult-to biopsy tumors; and detecting cancer at early stages. The latter can be limited by the small amounts of tumor-derived components shed into the circulation; furthermore, cfDNA assessment in all cancers can be confounded by clonal hematopoeisis of indeterminate potential, especially in the elderly. CTCs can be technically more difficult to isolate that cfDNA, but permit functional assays, as well as evaluation of CTC-derived DNA, RNA and proteins, including single-cell analysis. Blood biopsies are less invasive than tissue biopsies and hence amenable to serial collection, which can provide critical molecular information in real time. In conclusion, liquid biopsy is a powerful tool, and remarkable advances in this technology have impacted multiple aspects of precision oncology, from early diagnosis to management of refractory metastatic disease. Future research may focus on fluids beyond blood, such as ascites, effusions, urine, and cerebrospinal fluid, as well as methylation patterns and elements such as exosomes.<\/jats:p>","DOI":"10.1186\/s13045-022-01351-y","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T07:04:48Z","timestamp":1662966288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":937,"title":["Liquid biopsy: current technology and clinical applications"],"prefix":"10.1186","volume":"15","author":[{"given":"Mina","family":"Nikanjam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"1351_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143600","author":"JJ Adashek","year":"2021","unstructured":"Adashek JJ, Janku F, Kurzrock R. Signed in blood: circulating tumor dna in cancer diagnosis, treatment and screening. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13143600.","journal-title":"Cancers"},{"key":"1351_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092361","author":"R Agashe","year":"2020","unstructured":"Agashe R, Kurzrock R. Circulating tumor cells: from the laboratory to the cancer clinic. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12092361.","journal-title":"Cancers"},{"key":"1351_CR3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.21037\/tlcr.2016.10.02","volume":"5","author":"S Calabuig-Farinas","year":"2016","unstructured":"Calabuig-Farinas S, Jantus-Lewintre E, Herreros-Pomares A, Camps C. Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? Transl Lung Cancer Res. 2016;5:466\u201382.","journal-title":"Transl Lung Cancer Res"},{"key":"1351_CR4","doi-asserted-by":"crossref","first-page":"55632","DOI":"10.18632\/oncotarget.17184","volume":"8","author":"S Jia","year":"2017","unstructured":"Jia S, Zhang R, Li Z, Li J. Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. Oncotarget. 2017;8:55632\u201345.","journal-title":"Oncotarget"},{"key":"1351_CR5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3892\/etm.2015.2221","volume":"9","author":"BO Zhang","year":"2015","unstructured":"Zhang BO, Xu CW, Shao Y, et al. Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation. Exp Ther Med. 2015;9:1383\u20138.","journal-title":"Exp Ther Med"},{"key":"1351_CR6","first-page":"1409","volume":"17","author":"H Li","year":"2019","unstructured":"Li H, Jing C, Wu J, et al. Circulating tumor DNA detection: a potential tool for colorectal cancer management. Oncol Lett. 2019;17:1409\u201316.","journal-title":"Oncol Lett"},{"key":"1351_CR7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548\u201354.","journal-title":"Nat Med"},{"key":"1351_CR8","doi-asserted-by":"crossref","first-page":"136ra168","DOI":"10.1126\/scitranslmed.3003726","volume":"4","author":"T Forshew","year":"2012","unstructured":"Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4:136ra168.","journal-title":"Sci Transl Med"},{"key":"1351_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091399","author":"R Imperial","year":"2019","unstructured":"Imperial R, Nazer M, Ahmed Z, et al. Matched whole-genome sequencing (WGS) and whole-exome sequencing (WES) of tumor tissue with circulating tumor DNA (ctDNA) analysis: complementary modalities in clinical practice. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11091399.","journal-title":"Cancers"},{"key":"1351_CR10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrg2302","volume":"9","author":"AL McGuire","year":"2008","unstructured":"McGuire AL, Caulfield T, Cho MK. Research ethics and the challenge of whole-genome sequencing. Nat Rev Genet. 2008;9:152\u20136.","journal-title":"Nat Rev Genet"},{"key":"1351_CR11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-1-62703-607-8_13","volume":"1067","author":"R Wardenaar","year":"2013","unstructured":"Wardenaar R, Liu H, Colot V, et al. Evaluation of MeDIP-chip in the context of whole-genome bisulfite sequencing (WGBS-seq) in Arabidopsis. Methods Mol Biol. 2013;1067:203\u201324.","journal-title":"Methods Mol Biol"},{"key":"1351_CR12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1101\/gr.125872.111","volume":"22","author":"GC Hon","year":"2012","unstructured":"Hon GC, Hawkins RD, Caballero OL, et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res. 2012;22:246\u201358.","journal-title":"Genome Res"},{"key":"1351_CR13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-019-0735-4","volume":"12","author":"P Banko","year":"2019","unstructured":"Banko P, Lee SY, Nagygyorgy V, et al. Technologies for circulating tumor cell separation from whole blood. J Hematol Oncol. 2019;12:48.","journal-title":"J Hematol Oncol"},{"key":"1351_CR14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.molonc.2016.01.007","volume":"10","author":"MM Ferreira","year":"2016","unstructured":"Ferreira MM, Ramani VC, Jeffrey SS. Circulating tumor cell technologies. Mol Oncol. 2016;10:374\u201394.","journal-title":"Mol Oncol"},{"key":"1351_CR15","doi-asserted-by":"crossref","first-page":"54115","DOI":"10.1063\/1.4825395","volume":"7","author":"O Osman","year":"2013","unstructured":"Osman O, Toru S, Dumas-Bouchiat F, et al. Microfluidic immunomagnetic cell separation using integrated permanent micromagnets. Biomicrofluidics. 2013;7:54115.","journal-title":"Biomicrofluidics"},{"key":"1351_CR16","doi-asserted-by":"crossref","DOI":"10.1088\/0034-4885\/78\/1\/016601","volume":"78","author":"BD Plouffe","year":"2015","unstructured":"Plouffe BD, Murthy SK, Lewis LH. Fundamentals and application of magnetic particles in cell isolation and enrichment: a review. Rep Prog Phys. 2015;78: 016601.","journal-title":"Rep Prog Phys"},{"key":"1351_CR17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-11-0215","volume":"1","author":"CV Pecot","year":"2011","unstructured":"Pecot CV, Bischoff FZ, Mayer JA, et al. A novel platform for detection of CK+ and CK- CTCs. Cancer Discov. 2011;1:580\u20136.","journal-title":"Cancer Discov"},{"key":"1351_CR18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2018.01.002","volume":"125","author":"SJ Hao","year":"2018","unstructured":"Hao SJ, Wan Y, Xia YQ, et al. Size-based separation methods of circulating tumor cells. Adv Drug Deliv Rev. 2018;125:3\u201320.","journal-title":"Adv Drug Deliv Rev"},{"key":"1351_CR19","volume":"8","author":"H Chen","year":"2018","unstructured":"Chen H, Zhang Z, Wang B. Size- and deformability-based isolation of circulating tumor cells with microfluidic chips and their applications in clinical studies. AIP Adv. 2018;8: 120701.","journal-title":"AIP Adv"},{"key":"1351_CR20","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.18632\/oncotarget.24140","volume":"9","author":"TB Porras","year":"2018","unstructured":"Porras TB, Kaur P, Ring A, et al. Challenges in using liquid biopsies for gene expression profiling. Oncotarget. 2018;9:7036\u201353.","journal-title":"Oncotarget"},{"key":"1351_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010168","author":"P Hofman","year":"2021","unstructured":"Hofman P. Detecting resistance to therapeutic ALK inhibitors in tumor tissue and liquid biopsy markers: an update to a clinical routine practice. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10010168.","journal-title":"Cells"},{"key":"1351_CR22","first-page":"234","volume":"6","author":"Y Wu","year":"2016","unstructured":"Wu Y, Park KJ, Deighan C, et al. Multiparameter evaluation of the heterogeneity of circulating tumor cells using integrated RNA in situ hybridization and immunocytochemical analysis. Front Oncol. 2016;6:234.","journal-title":"Front Oncol"},{"key":"1351_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081810","author":"S Rosswag","year":"2021","unstructured":"Rosswag S, Cotarelo CL, Pantel K, et al. Functional characterization of circulating tumor cells (CTCs) from metastatic ER+\/HER2- breast cancer reveals dependence on HER2 and FOXM1 for endocrine therapy resistance and tumor cell survival: implications for treatment of ER+\/HER2- breast cancer. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13081810.","journal-title":"Cancers"},{"key":"1351_CR24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","volume":"159","author":"D Gao","year":"2014","unstructured":"Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159:176\u201387.","journal-title":"Cell"},{"key":"1351_CR25","doi-asserted-by":"crossref","first-page":"12383","DOI":"10.18632\/oncotarget.2592","volume":"5","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Shiratsuchi H, Lin J, et al. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget. 2014;5:12383\u201397.","journal-title":"Oncotarget"},{"key":"1351_CR26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/science.1253533","volume":"345","author":"M Yu","year":"2014","unstructured":"Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345:216\u201320.","journal-title":"Science"},{"key":"1351_CR27","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1158\/0008-5472.CAN-14-2613","volume":"75","author":"L Cayrefourcq","year":"2015","unstructured":"Cayrefourcq L, Mazard T, Joosse S, et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 2015;75:892\u2013901.","journal-title":"Cancer Res"},{"key":"1351_CR28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18632\/oncoscience.8","volume":"1","author":"E Rossi","year":"2014","unstructured":"Rossi E, Rugge M, Facchinetti A, et al. Retaining the long-survive capacity of circulating tumor cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients. Oncoscience. 2014;1:49\u201356.","journal-title":"Oncoscience"},{"key":"1351_CR29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nbt.2576","volume":"31","author":"I Baccelli","year":"2013","unstructured":"Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31:539\u201344.","journal-title":"Nat Biotechnol"},{"key":"1351_CR30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nm.3600","volume":"20","author":"CL Hodgkinson","year":"2014","unstructured":"Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20:897\u2013903.","journal-title":"Nat Med"},{"key":"1351_CR31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1634\/theoncologist.2019-0636","volume":"25","author":"JJ Adashek","year":"2020","unstructured":"Adashek JJ, Kato S, Ferrara R, et al. Hyperprogression and immune checkpoint inhibitors: hype or progress? Oncologist. 2020;25:94\u20138.","journal-title":"Oncologist"},{"key":"1351_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001504","author":"B Ricciuti","year":"2021","unstructured":"Ricciuti B, Jones G, Severgnini M, et al. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001504.","journal-title":"J Immunother Cancer"},{"key":"1351_CR33","doi-asserted-by":"crossref","first-page":"2052410","DOI":"10.1080\/2162402X.2022.2052410","volume":"11","author":"S Kato","year":"2022","unstructured":"Kato S, Li B, Adashek JJ, et al. Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting. Oncoimmunology. 2022;11:2052410.","journal-title":"Oncoimmunology"},{"key":"1351_CR34","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10:1842\u201353.","journal-title":"Cancer Discov"},{"key":"1351_CR35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/1535-7163.MCT-18-0535","volume":"18","author":"TJ Jensen","year":"2019","unstructured":"Jensen TJ, Goodman AM, Kato S, et al. Genome-wide sequencing of cell-free DNA identifies copy-number alterations that can be used for monitoring response to immunotherapy in cancer patients. Mol Cancer Ther. 2019;18:448\u201358.","journal-title":"Mol Cancer Ther"},{"key":"1351_CR36","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598\u2013608.","journal-title":"Mol Cancer Ther"},{"key":"1351_CR37","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jamaoncol.2020.1046","volume":"6","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Ghidini M, Ghidini A, Tomasello G. Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis. JAMA Oncol. 2020;6:1068\u201371.","journal-title":"JAMA Oncol"},{"key":"1351_CR38","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-17-1439","volume":"23","author":"Y Khagi","year":"2017","unstructured":"Khagi Y, Goodman AM, Daniels GA, et al. Hypermutated Circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res. 2017;23:5729\u201336.","journal-title":"Clin Cancer Res"},{"key":"1351_CR39","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","volume":"24","author":"DR Gandara","year":"2018","unstructured":"Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24:1441\u20138.","journal-title":"Nat Med"},{"key":"1351_CR40","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1158\/1078-0432.CCR-19-1372","volume":"25","author":"A Georgiadis","year":"2019","unstructured":"Georgiadis A, Durham JN, Keefer LA, et al. Noninvasive detection of microsatellite instability and high tumor mutation burden in cancer patients treated with PD-1 blockade. Clin Cancer Res. 2019;25:7024\u201334.","journal-title":"Clin Cancer Res"},{"key":"1351_CR41","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/annonc\/mdv177","volume":"26","author":"J Tie","year":"2015","unstructured":"Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26:1715\u201322.","journal-title":"Ann Oncol"},{"key":"1351_CR42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32:229\u201339.","journal-title":"Ann Oncol"},{"key":"1351_CR43","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0715-827b","volume":"21","author":"G Siravegna","year":"2015","unstructured":"Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:827.","journal-title":"Nat Med"},{"key":"1351_CR44","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fonc.2020.00466","volume":"10","author":"H Cao","year":"2020","unstructured":"Cao H, Liu X, Chen Y, et al. Circulating tumor DNA Is capable of monitoring the therapeutic response and resistance in advanced colorectal cancer patients undergoing combined target and chemotherapy. Front Oncol. 2020;10:466.","journal-title":"Front Oncol"},{"key":"1351_CR45","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz260.078","volume":"30","author":"S Ortiz-Cuaran","year":"2019","unstructured":"Ortiz-Cuaran S, Mezquita L, Swalduz A, et al. 1556P\u2014circulating tumour DNA (ctDNA) analysis depicts mechanisms of resistance and tumour response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC). Ann Oncol. 2019;30: v641.","journal-title":"Ann Oncol"},{"key":"1351_CR46","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s43018-020-0047-1","volume":"1","author":"P Razavi","year":"2020","unstructured":"Razavi P, Dickler MN, Shah PD, et al. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer. 2020;1:382\u201393.","journal-title":"Nat Cancer"},{"key":"1351_CR47","doi-asserted-by":"crossref","first-page":"66020","DOI":"10.18632\/oncotarget.11791","volume":"7","author":"F Ma","year":"2016","unstructured":"Ma F, Zhu W, Guan Y, et al. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Oncotarget. 2016;7:66020\u201331.","journal-title":"Oncotarget"},{"key":"1351_CR48","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","volume":"368","author":"SJ Dawson","year":"2013","unstructured":"Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199\u2013209.","journal-title":"N Engl J Med"},{"key":"1351_CR49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002198","volume":"13","author":"CA Parkinson","year":"2016","unstructured":"Parkinson CA, Gale D, Piskorz AM, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 2016;13: e1002198.","journal-title":"PLoS Med"},{"key":"1351_CR50","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1158\/1078-0432.CCR-11-3148","volume":"18","author":"EA Punnoose","year":"2012","unstructured":"Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012;18:2391\u2013401.","journal-title":"Clin Cancer Res"},{"key":"1351_CR51","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883\u201392.","journal-title":"N Engl J Med"},{"key":"1351_CR52","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.1038\/ncomms9760","volume":"6","author":"M Murtaza","year":"2015","unstructured":"Murtaza M, Dawson SJ, Pogrebniak K, et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 2015;6:8760.","journal-title":"Nat Commun"},{"key":"1351_CR53","volume":"8","author":"D Pan","year":"2021","unstructured":"Pan D, Jia D. Application of single-cell multi-omics in dissecting cancer cell plasticity and tumor heterogeneity. Front Mol Biosci. 2021;8: 757024.","journal-title":"Front Mol Biosci"},{"key":"1351_CR54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ccell.2017.01.002","volume":"31","author":"A Bardelli","year":"2017","unstructured":"Bardelli A, Pantel K. Liquid Biopsies, What We Do Not Know (Yet). Cancer Cell. 2017;31:172\u20139.","journal-title":"Cancer Cell"},{"key":"1351_CR55","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.trecan.2020.11.002","volume":"7","author":"S Kato","year":"2021","unstructured":"Kato S, Alsafar A, Walavalkar V, et al. Cancer of unknown primary in the molecular era. Trends Cancer. 2021;7:465\u201377.","journal-title":"Trends Cancer"},{"key":"1351_CR56","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-17-0628","volume":"77","author":"S Kato","year":"2017","unstructured":"Kato S, Krishnamurthy N, Banks KC, et al. Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary. Cancer Res. 2017;77:4238\u201346.","journal-title":"Cancer Res"},{"key":"1351_CR57","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00011","author":"S Kato","year":"2021","unstructured":"Kato S, Weipert C, Gumas S, et al. Therapeutic actionability of circulating cell-free DNA alterations in carcinoma of unknown primary. JCO Precis Oncol. 2021. https:\/\/doi.org\/10.1200\/PO.21.00011.","journal-title":"JCO Precis Oncol"},{"key":"1351_CR58","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1158\/1535-7163.MCT-17-1038","volume":"18","author":"R Shatsky","year":"2019","unstructured":"Shatsky R, Parker BA, Bui NQ, et al. Next-generation sequencing of tissue and circulating tumor DNA: the UC San Diego Moores center for personalized cancer therapy experience with breast malignancies. Mol Cancer Ther. 2019;18:1001\u201311.","journal-title":"Mol Cancer Ther"},{"key":"1351_CR59","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1158\/1078-0432.CCR-18-1128","volume":"24","author":"S Kato","year":"2018","unstructured":"Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. Clin Cancer Res. 2018;24:6248\u201356.","journal-title":"Clin Cancer Res"},{"key":"1351_CR60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/1878-0261.12791","volume":"15","author":"LM Charo","year":"2021","unstructured":"Charo LM, Eskander RN, Okamura R, et al. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Mol Oncol. 2021;15:67\u201379.","journal-title":"Mol Oncol"},{"key":"1351_CR61","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00180","author":"S Kato","year":"2019","unstructured":"Kato S, Okamura R, Mareboina M, et al. Revisiting epidermal growth factor receptor (EGFR) amplification as a target for anti-EGFR therapy: analysis of cell-free circulating tumor DNA in patients with advanced malignancies. JCO Precis Oncol. 2019. https:\/\/doi.org\/10.1200\/PO.18.00180.","journal-title":"JCO Precis Oncol"},{"key":"1351_CR62","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1158\/1535-7163.MCT-18-0965","volume":"18","author":"IS Choi","year":"2019","unstructured":"Choi IS, Kato S, Fanta PT, et al. Genomic profiling of blood-derived circulating tumor DNA from patients with colorectal cancer: implications for response and resistance to targeted therapeutics. Mol Cancer Ther. 2019;18:1852\u201362.","journal-title":"Mol Cancer Ther"},{"key":"1351_CR63","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/ijc.33230","volume":"148","author":"R Okamura","year":"2021","unstructured":"Okamura R, Kurzrock R, Mallory RJ, et al. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. Int J Cancer. 2021;148:702\u201312.","journal-title":"Int J Cancer"},{"key":"1351_CR64","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-16-2497","volume":"23","author":"MC Schwaederle","year":"2017","unstructured":"Schwaederle MC, Patel SP, Husain H, et al. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res. 2017;23:5101\u201311.","journal-title":"Clin Cancer Res"},{"key":"1351_CR65","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/annonc\/mdz046","volume":"30","author":"BT Li","year":"2019","unstructured":"Li BT, Janku F, Jung B, et al. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the actionable genome consortium. Ann Oncol. 2019;30:597\u2013603.","journal-title":"Ann Oncol"},{"key":"1351_CR66","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","volume":"25","author":"SB Maron","year":"2019","unstructured":"Maron SB, Chase LM, Lomnicki S, et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin Cancer Res. 2019;25:7098\u2013112.","journal-title":"Clin Cancer Res"},{"key":"1351_CR67","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","volume":"1","author":"ES Antonarakis","year":"2015","unstructured":"Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1:582\u201391.","journal-title":"JAMA Oncol"},{"key":"1351_CR68","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1158\/1078-0432.CCR-16-0318","volume":"22","author":"M Schwaederle","year":"2016","unstructured":"Schwaederle M, Husain H, Fanta PT, et al. Use of liquid biopsies in clinical oncology: pilot experience in 168 patients. Clin Cancer Res. 2016;22:5497\u2013505.","journal-title":"Clin Cancer Res"},{"key":"1351_CR69","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00204","author":"P Vu","year":"2020","unstructured":"Vu P, Khagi Y, Riviere P, et al. Total number of alterations in liquid biopsies is an independent predictor of survival in patients with advanced cancers. JCO Precis Oncol. 2020. https:\/\/doi.org\/10.1200\/PO.19.00204.","journal-title":"JCO Precis Oncol"},{"key":"1351_CR70","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1158\/1535-7163.MCT-20-1066","volume":"20","author":"TJ Jensen","year":"2021","unstructured":"Jensen TJ, Goodman AM, Ellison CK, et al. Genome-wide sequencing of cell-free dna enables detection of copy-number alterations in patients with cancer where tissue biopsy is not feasible. Mol Cancer Ther. 2021;20:2274\u20139.","journal-title":"Mol Cancer Ther"},{"key":"1351_CR71","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1245\/s10434-018-6561-z","volume":"25","author":"JM Baumgartner","year":"2018","unstructured":"Baumgartner JM, Raymond VM, Lanman RB, et al. Preoperative circulating tumor DNA in patients with peritoneal carcinomatosis is an independent predictor of progression-free survival. Ann Surg Oncol. 2018;25:2400\u20138.","journal-title":"Ann Surg Oncol"},{"key":"1351_CR72","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1158\/1535-7163.MCT-20-0097","volume":"19","author":"S Rosenberg","year":"2020","unstructured":"Rosenberg S, Okamura R, Kato S, et al. Survival implications of the relationship between tissue versus circulating tumor DNA TP53 mutations-a perspective from a real-world precision medicine cohort. Mol Cancer Ther. 2020;19:2612\u201320.","journal-title":"Mol Cancer Ther"},{"key":"1351_CR73","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ijc.32510","volume":"146","author":"K Mardinian","year":"2020","unstructured":"Mardinian K, Okamura R, Kato S, Kurzrock R. Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. Int J Cancer. 2020;146:566\u201376.","journal-title":"Int J Cancer"},{"key":"1351_CR74","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-018-0610-8","volume":"11","author":"S Ikeda","year":"2018","unstructured":"Ikeda S, Schwaederle M, Mohindra M, et al. MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. J Hematol Oncol. 2018;11:76.","journal-title":"J Hematol Oncol"},{"key":"1351_CR75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.594","author":"L Cavallone","year":"2019","unstructured":"Cavallone L, Aguilar A, Aldamry M, et al. Circulating tumor DNA (ctDNA) during and after neoadjuvant chemotherapy and prior to surgery is a powerful prognostic factor in triple-negative breast cancer (TNBC). J Clin Oncol. 2019. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.594.","journal-title":"J Clin Oncol"},{"key":"1351_CR76","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1200\/JCO.2017.35.15_suppl.3521","volume":"35","author":"J Tie","year":"2017","unstructured":"Tie J, Cohen J, Wang Y, et al. The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC). J Clin Oncol. 2017;35:3521\u20133521.","journal-title":"J Clin Oncol"},{"key":"1351_CR77","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-019-0824-4","volume":"12","author":"H Patel","year":"2019","unstructured":"Patel H, Okamura R, Fanta P, et al. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019;12:130.","journal-title":"J Hematol Oncol"},{"key":"1351_CR78","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1158\/1078-0432.CCR-18-0922","volume":"24","author":"L Cabel","year":"2018","unstructured":"Cabel L, Jeannot E, Bieche I, et al. Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal squamous cell carcinoma. Clin Cancer Res. 2018;24:5767\u201371.","journal-title":"Clin Cancer Res"},{"key":"1351_CR79","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2021.39.3_suppl.102","volume":"39","author":"G Anandappa","year":"2021","unstructured":"Anandappa G, Starling N, Begum R, et al. Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC). J Clin Oncol. 2021;39:102\u2013102.","journal-title":"J Clin Oncol"},{"key":"1351_CR80","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1002\/ijc.33481","volume":"148","author":"R Okamura","year":"2021","unstructured":"Okamura R, Piccioni DE, Boichard A, et al. High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment. Int J Cancer. 2021;148:2839\u201347.","journal-title":"Int J Cancer"},{"key":"1351_CR81","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2019.7383","volume":"18","author":"W Nie","year":"2020","unstructured":"Nie W, Qian J, Xu MD, et al. Prognostic and predictive value of blood tumor mutational burden in patients with lung cancer treated with docetaxel. J Natl Compr Canc Netw. 2020;18:582\u20139.","journal-title":"J Natl Compr Canc Netw"},{"key":"1351_CR82","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781\u201391.","journal-title":"N Engl J Med"},{"key":"1351_CR83","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","volume":"15","author":"FC Bidard","year":"2014","unstructured":"Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15:406\u201314.","journal-title":"Lancet Oncol"},{"key":"1351_CR84","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.2007.13.6523","volume":"26","author":"K Pachmann","year":"2008","unstructured":"Pachmann K, Camara O, Kavallaris A, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol. 2008;26:1208\u201315.","journal-title":"J Clin Oncol"},{"key":"1351_CR85","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1373\/clinchem.2017.277517","volume":"64","author":"NG Dharajiya","year":"2018","unstructured":"Dharajiya NG, Grosu DS, Farkas DH, et al. Incidental detection of maternal neoplasia in noninvasive prenatal testing. Clin Chem. 2018;64:329\u201335.","journal-title":"Clin Chem"},{"key":"1351_CR86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-022-00088-6","volume":"2","author":"J Hinestrosa","year":"2022","unstructured":"Hinestrosa J, Kurzrock R, Lewis J, et al. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med. 2022;2:1\u20139.","journal-title":"Commun Med"},{"key":"1351_CR87","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926\u201330.","journal-title":"Science"},{"key":"1351_CR88","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/nmat4997","volume":"16","author":"RH Xu","year":"2017","unstructured":"Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16:1155\u201361.","journal-title":"Nat Mater"},{"key":"1351_CR89","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/annonc\/mdy119","volume":"29","author":"L Liu","year":"2018","unstructured":"Liu L, Toung JM, Jassowicz AF, et al. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann Oncol. 2018;29:1445\u201353.","journal-title":"Ann Oncol"},{"key":"1351_CR90","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745\u201359.","journal-title":"Ann Oncol"},{"key":"1351_CR91","doi-asserted-by":"crossref","first-page":"30e31","DOI":"10.1016\/j.jtct.2021.10.007","volume":"28","author":"AM Goodman","year":"2022","unstructured":"Goodman AM, Holden KA, Jeong AR, et al. Assessing CAR T-Cell therapy response using genome-wide sequencing of cell-free DNA in patients with B-Cell lymphomas. Transplant Cell Ther. 2022;28:30e31\u20137.","journal-title":"Transplant Cell Ther"},{"key":"1351_CR92","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1038\/s41467-021-24994-w","volume":"12","author":"D Mathios","year":"2021","unstructured":"Mathios D, Johansen JS, Cristiano S, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021;12:5060.","journal-title":"Nat Commun"},{"key":"1351_CR93","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570:385\u20139.","journal-title":"Nature"},{"key":"1351_CR94","first-page":"E10925","volume":"115","author":"P Jiang","year":"2018","unstructured":"Jiang P, Sun K, Tong YK, et al. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2018;115:E10925\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1351_CR95","volume":"81","author":"W Guo","year":"2022","unstructured":"Guo W, Chen X, Liu R, et al. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling. EBioMedicine. 2022;81: 104131.","journal-title":"EBioMedicine"},{"key":"1351_CR96","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1158\/1078-0432.CCR-17-0454","volume":"23","author":"H Husain","year":"2017","unstructured":"Husain H, Melnikova VO, Kosco K, et al. Monitoring daily dynamics of early tumor response to targeted therapy by detecting circulating tumor DNA in urine. Clin Cancer Res. 2017;23:4716\u201323.","journal-title":"Clin Cancer Res"},{"key":"1351_CR97","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.7150\/thno.34070","volume":"9","author":"L Tong","year":"2019","unstructured":"Tong L, Ding N, Tong X, et al. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. Theranostics. 2019;9:5532\u201341.","journal-title":"Theranostics"},{"key":"1351_CR98","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4143\/crt.2019.700","volume":"52","author":"MR Han","year":"2020","unstructured":"Han MR, Lee SH, Park JY, et al. Clinical implications of circulating tumor DNA from ascites and serial plasma in ovarian cancer. Cancer Res Treat. 2020;52:779\u201388.","journal-title":"Cancer Res Treat"},{"key":"1351_CR99","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3324\/haematol.2019.241208","volume":"106","author":"S Bobillo","year":"2021","unstructured":"Bobillo S, Crespo M, Escudero L, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2021;106:513\u201321.","journal-title":"Haematologica"},{"key":"1351_CR100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/gtmb.2018.0189","volume":"23","author":"S Jain","year":"2019","unstructured":"Jain S, Lin SY, Song W, Su YH. Urine-Based Liquid Biopsy for Nonurological Cancers. Genet Test Mol Biomark. 2019;23:277\u201383.","journal-title":"Genet Test Mol Biomark"},{"key":"1351_CR101","doi-asserted-by":"crossref","first-page":"473","DOI":"10.21037\/tlcr.2017.05.08","volume":"6","author":"DW Su","year":"2017","unstructured":"Su DW, Nieva J. Biophysical technologies for understanding circulating tumor cell biology and metastasis. Transl Lung Cancer Res. 2017;6:473\u201385.","journal-title":"Transl Lung Cancer Res"},{"key":"1351_CR102","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1126\/science.1235226","volume":"341","author":"V Plaks","year":"2013","unstructured":"Plaks V, Koopman CD, Werb Z. Circulating tumor cells. Science. 2013;341:1186\u20138.","journal-title":"Science"},{"key":"1351_CR103","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1634\/theoncologist.2020-0246","volume":"25","author":"P Narayan","year":"2020","unstructured":"Narayan P, Ghosh S, Philip R, et al. State of the science and future directions for liquid biopsies in drug development. Oncologist. 2020;25:730\u20132.","journal-title":"Oncologist"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01351-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-022-01351-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01351-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T09:20:43Z","timestamp":1664961643000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01351-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1351"],"URL":"https:\/\/doi.org\/10.1186\/s13045-022-01351-y","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"26 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Kato serves as a consultant for Foundation Medicine, NeoGenomics and CureMatch. He receives speaker\u2019s fee from Roche and advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta and OmniSeq. Dr. Kurzrock has the following disclosure information: Stock and Other Equity Interests (IDbyDNA, CureMatch, Inc., and Soluventis); Consulting or Advisory Role (Gaido, LOXO, X-Biotech, Actuate Therapeutics, Roche, NeoMed, Soluventis, Pfizer, and Merck); Speaker\u2019s fee (Roche); Research Funding (Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Konica Minolta, DeBiopharm, Boerhringer Ingelheim, and OmniSeq [All institutional]); Board Member (CureMatch, Inc., and CureMetrix, Inc.). Dr. Nikanjam own Genentech stock.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}